Pharmaceutical Technology

FEBRUARY 22, 2023

Developed by Sanofi and Regeneron, Praluent was approved by the FDA in July 2015. Both drugs come with a high price tag. Since April 2020, Sanofi is responsible for Praluent outside of the US, while Regeneron handles its sale in the US. Amgen’s Repatha was greenlit a month later. However, the case was brought back.

Antibody 262

Antibody Drugs Sales Protein 262

pharmaphorum

AUGUST 25, 2022

The category is getting increasingly crowed, with Pfizer also anticipating approval of its BCMA-targeting bispecific elranatamab in the coming months, with several more multiple myeloma bispecifics coming through the pipeline from the likes of Regeneron, AbbVie, Amgen and Roche.

Antibody 98

Antibody Marketing Drugs Medicine 98

Pharmaceutical Technology

MAY 15, 2023

Innovation S-curve for the pharmaceutical industry Peptide nano-particle conjugates is a key innovation area in the pharmaceutical industry By tagging peptides with nanoparticles, peptide nano-particle conjugates allow enhanced control over their biological behaviour, overcoming intrinsic limitations of the individual materials.

Antibody 130

Antibody DNA Development Vaccination 130

Delveinsight

FEBRUARY 23, 2021

The company plans to use the capital to expand its pipeline of protein-based vaccines and biologic cancer therapies utilizing its innovative and proprietary Trimer-Tag technology platform. The approval is granted to Sanofi and Regeneron Pharmaceuticals.

In-Vitro 52

In-Vitro Vaccination Vaccine Licensing 52

The Pharma Data

MAY 5, 2021

India approves Roche/Regeneron antibody cocktail to treat COVID-19 ( Reuters ). AbbVie’s Humira regains top pharma TV spender spot, while sibling brands Rinvoq and Skyrizi tag along ( Fierce ). Now its failures are threatening much of the world ( Reuters ). Coronavirus Pandemic.

Vaccination 52

Vaccination Vaccine Gene Therapy Contract Packaging 52

Drug Discovery World

NOVEMBER 13, 2023

Qingyan Hu, PhD, Associate Director, Protein Formulation Development, Regeneron Pharmaceuticals, on: ‘Improving safety and dose accuracy of IV administration for protein drug products’. Fabian Mohr, PhD, Vice President Research & Development, IBA Lifesciences, on: ‘Developing a robust affinity tag platform using engineered streptavidin’.

Protein 59

Protein Antibody Engineer Scientist 59

Drug Discovery World

NOVEMBER 9, 2023

Dimitris Skokos, PhD, Senior Director, Cancer Immunology, Regeneron Pharmaceuticals, on: ‘Tumour-targeted costimulation via CD28 bispecific antibodies: Turning immunotherapy “cold” tumours “hot”’.

Engineer 52

Engineer Antibody Protein In-Vivo 52